The development program for Sage Therapeutics Inc.'s brexanolone for the treatment of postpartum depression (PPD) received a ringing endorsement during a joint meeting of the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM). Voting 18-0 with no abstentions, members indicated that Sage presented "substantial evidence" to support effectiveness of the type A gamma-aminobutyric acid (GABAA) receptor modulator in the indication, which has no approved medications.